BTG receives CE Mark certification for radiopaque drug-eluting bead

BTG received Class III CE Mark certification for its DC Bead LUMI, a radiopaque drug-eluting bead for patients with hepatocellular carcinoma and malignant colorectal cancer metastasized to the liver, according to a press release.

The DC Bead LUMI can be loaded with doxorubicin or irinotecan for the local treatment of tumors. It was designed with a tri-iodobenzyl moiety to provide long-term radiopacity, making the bead visible during and after transarterial chemoembolization (TACE) procedures.

“The ability to see bead location during TACE procedures is a key step in enhancing the quality and potentially minimizing complications of the procedure, and can help improve treatment outcomes compared to current techniques,” Tobias Jakobs, MD, of the Hospital of the Order of St. John of God, Munich, said in the release. “More importantly, the lasting radiopacity of DC Bead LUMI means I can show patients that treatment has been placed exactly where it’s needed.”

BTG developed the DC Bead LUMI using the same core chemistry as the previous CE Mark approved DC Bead.

Reference: www.btg-im.com